Phase 2 N=60 Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
Hepatitis B, Chronic
Primary: Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment — 2; 0; 0; 0 participants
Phase 2 N=30 IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Multiple Myeloma
Primary: Percentage of Participants With Overall Disease Response at Month 6 — 20.0; 70.0; 10.0 Percentage of participants
Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Phase 2 N=192 Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
Skin Diseases, Infectious · Skin Diseases, Bacterial
Primary: Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set — 98.2; 94.4; 94.4 Percentage of participants
Phase 2 N=121 Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain
Osteoarthritis
Primary: Change From Baseline in the Average Daily Worst Pain Intensity Score at Week 4 — 6.4; 6.5; -1.8; -1.8 Score on a scale
Phase 2 N=75 A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
Colorectal Cancer
Primary: Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression — 6.3; 5.1 months
Phase 2 N=124 PRM-151 in the Prevention of Scarring Following Trabeculectomy
Glaucoma
Primary: Safety of Subconjunctival Injection — 274; 220; 166; 113 Number of occurrences
Phase 2 N=40 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Colorectal Adenoma · Colorectal Carcinoma
Primary: Number of Subjects Witha Change (IMPROVEMENT) in Colo-rectal Adenocarcinoma as Measured by Cyclooxygenase-2 Activity After 7 Days of Celecoxib — 2.0; 2.0 Participant
Phase 2 N=20 Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%
Erythematous Rosacea
Primary: Cmax - Maximum Systemic Concentration of Brimonidine — NA; NA pg/mL
Phase 2 N=903 An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Autism Spectrum Disorder (ASD) · Autism · Autistic Disorder
Primary: Number of Confirmed Social Responsiveness Scale (SRS) Responders — 517; 351 participants
Phase 2 N=262 Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder
Major Depressive Disorder
Primary: Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score — -1.5; -1.8; -1.9 units on a scale
Phase 2 N=54 Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy
Airway Obstruction · Apnea · Hypopnea
Primary: RI Events in the cNEP Group Compared to the no cNEP Group, Where RI is Defined as Either: i Oxygen Saturation < 90% or ii. Apneas/Hypopneas of > 15 Sec Duration i…
Phase 2 N=222 Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax) — -1.69; -7.84; -6.69 cmH2O
Phase 2 N=104 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
Gastroesophageal Reflux Disease
Primary: Percent of Participants Who Experience Each Treatment Emergent Adverse Event Experienced by ≥5% of Participants While Receiving Dexlansoprazole During the 4 Week…